![Erich Felber](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Erich Felber
Plus aucun poste en cours
Provenance du réseau au premier degré de Erich Felber
Entité | Type d'entité | Industrie | |
---|---|---|---|
Micromet AG
![]() Micromet AG Pharmaceuticals: MajorHealth Technology Micromet AG developed, manufactured and marketed novel antibody derived therapeutics for the treatment and control of cancer, inflammatory and autoimmune diseases. It's goal was to commercialize products in these indication areas that have significant unmet medical needs. Founded in 1993, the company was headquartered in Munich, Germany.
6
| Extinct | Pharmaceuticals: Major | 6 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Erich Felber via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
Amgen Rockville, Inc.
![]() Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Biotechnology | Corporate Officer/Principal Director/Board Member Chief Executive Officer Chief Tech/Sci/R&D Officer | |
WEREWOLF THERAPEUTICS, INC. | Pharmaceuticals: Major | Founder | |
Max-Planck-Institute for Molecular Genetics | College/University | Doctorate Degree | |
Ludwig-Maximilians-Universität München | College/University | Doctorate Degree | |
F. Hoffmann-La Roche Ltd.
![]() F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
University of Freiburg | College/University | Corporate Officer/Principal | |
European Molecular Biology Organization | Corporate Officer/Principal | ||
iOmx Therapeutics AG
![]() iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | Biotechnology | Founder | |
TCR2 THERAPEUTICS INC. | Pharmaceuticals: Major | Founder | |
HARPOON THERAPEUTICS, INC. | Biotechnology | Founder | |
MPM BioImpact, Inc
![]() MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor | |
Maverick Therapeutics, Inc.
![]() Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | Biotechnology | Founder | |
Amgen Research (Munich) GmbH
![]() Amgen Research (Munich) GmbH Metal FabricationProducer Manufacturing Part of Amgen, Inc., Amgen Research (Munich) GmbH is a biotechnology company based in Munich, Germany. The company has over 850 employees working at two locations in Germany. Amgen Scholars Europe Programs offer practical research experience to 100 students from all over Europe every summer. The company utilizes biotechnological possibilities to develop innovative treatments for diseases. The company continuously develops new substances to provide biopharmaceuticals to patients worldwide with serious illnesses. The CEOs of the company are Peter Kufer and Robert Saller. Amgen Research (Munich was acquired by ECKA Granulate GmbH & Co. KG from Aurubis AG on June 13, 2002. | Metal Fabrication | Chief Tech/Sci/R&D Officer | |
CULLINAN THERAPEUTICS, INC. | Pharmaceuticals: Major | Founder | |
Autolus Holdings (UK) Ltd.
![]() Autolus Holdings (UK) Ltd. BiotechnologyHealth Technology Part of Autolus Therapeutics Plc, Autolus Holdings (UK) Ltd. is a holding British company that operates subsidiaries engaged in pharmaceutical research and development activities. The company is based in London, UK and was founded in 2018. | Biotechnology | Director/Board Member | |
Crossbow Therapeutics, Inc.
![]() Crossbow Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Crossbow Therapeutics, Inc. is a biotechnology company that aims to improve the lives of people with cancer by developing next-generation immunotherapies. The company is based in Cambridge, MA, and the CEO of the company is Briggs W. Morrison. The company's T-bolt™ therapies are designed to target previously unreachable cancer cell targets with high precision. Crossbow's approach is efficient and selective, allowing them to target the entire universe of cancer proteins, which expands the potential of antibody therapy to address many types of cancer. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
ABLYNX | Biotechnology | Corporate Officer/Principal | |
Eberhard Karls Universität Tübingen | College/University | Doctorate Degree | |
ARGENX SE | Pharmaceuticals: Other | Founder | |
The Scripps Research Institute
![]() The Scripps Research Institute Other Consumer ServicesConsumer Services The Scripps Research Institute is a private, non-profit research organizations that performs basic biomedical research in molecular & cellular biology, chemistry, immunology and neuroscience. They receive the majority of its funding from federal agencies such as the National Institutes of Health. The organization also partners with pharmaceutical companies and is affiliated with the Scripps hospital group. The organization was founded in 1955 and is headquartered in La Jolla, California. | College/University | Corporate Officer/Principal | |
MORPHOSYS AG | Biotechnology | Chief Tech/Sci/R&D Officer | |
Freie Universität Berlin | College/University | Doctorate Degree | |
MERCK KGAA | Pharmaceuticals: Major | Corporate Officer/Principal | |
Tango Therapeutics Sub, Inc.
![]() Tango Therapeutics Sub, Inc. BiotechnologyHealth Technology Tango Therapeutics, Inc. develops transformational new drugs for cancer patients. The company was founded by Alan Ashworth, Jos? Baselga, Levi Garraway, Timothy K. Lu, Antoni Ribas and William G. Kaelin, Jr. in 2017 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
Sandoz International GmbH
![]() Sandoz International GmbH Pharmaceuticals: GenericHealth Technology Sandoz International GmbH develops and manufactures generic pharmaceuticals. It produces finished dosage forms of such off-patent drugs as diabetes treatment Glucophage, GERD drug Prilosec, and cholesterol. The company was founded in 1996 and is headquartered in Holzkirchen, Austria. | Pharmaceuticals: Generic | Corporate Officer/Principal | |
NOVARTIS AG | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
TANGO THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
HOOKIPA PHARMA INC. | Biotechnology | Director/Board Member | |
Amgen NV
![]() Amgen NV Pharmaceuticals: MajorHealth Technology Part of Amgen, Inc., Amgen NV is a pharmaceutical company based in Diegem, Belgium. The Belgian company is focused on developing innovative therapies to address serious illnesses and improve the lives of patients. Amgen is committed to advancing scientific research and delivering high-quality medicines to patients worldwide. The CEO of the company is Gabor Sztaniszlav. | Pharmaceuticals: Major | Corporate Officer/Principal | |
TeGenero AG
![]() TeGenero AG Pharmaceuticals: MajorHealth Technology TeGenero AG discovers and develops novel therapeutics. It is a biopharmaceutical company providing services in the identification and development of effective and applicable therapeutics for the treatment of severe immunological disorders. It's first development candidate TGN1412, a SuperMAB with specificity for the T cell surface receptor CD28 is in non-clinical development. Clinical applications of SuperMAB and its derived compounds are expected to solve unmet medical needs in the fields of cancer-related immunodeficiencies such as B-cell chronic lymphocytic leukaemia and autoimmune/inflammatory diseases like rheumatoid arthritis. The company was founded in 2000 and is headquartered in Wurzburg, Germany. | Pharmaceuticals: Major | Director/Board Member | |
Kymab Group Ltd.
![]() Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Pharmaceuticals: Major | Director/Board Member | |
Swiss Federal Institute of Technology | College/University | Doctorate Degree | |
Zeneca Pharmaceuticals
![]() Zeneca Pharmaceuticals Pharmaceuticals: MajorHealth Technology Zeneca Pharmaceuticals manufactures medicines. | Pharmaceuticals: Major | Corporate Officer/Principal | |
University of Gottingen | College/University | Undergraduate Degree | |
ISA Pharmaceuticals BV
![]() ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Corporate Officer/Principal | |
NBE-Therapeutics AG
![]() NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | Biotechnology | Director/Board Member | |
Santarus, Inc.
![]() Santarus, Inc. Pharmaceuticals: MajorHealth Technology Santarus, Inc. operates as a biopharmaceutical company. The company was founded on December 6, 1996 and is headquartered in Bridgewater, NJ. | Pharmaceuticals: Major | Director/Board Member | |
The University of Sheffield | College/University | Doctorate Degree | |
SV Health Investors LLP
![]() SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Investment Managers | Private Equity Investor | |
Roche Products Ltd.
![]() Roche Products Ltd. Pharmaceuticals: MajorHealth Technology Roche Products Ltd. manufactures diagnostic, diabetes, and pharmaceutical products. The company was founded on December 14, 1908 and is headquartered in Welwyn Garden City, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Healthcare Royalty Management LLC
![]() Healthcare Royalty Management LLC Investment ManagersFinance Healthcare Royalty Management LLC (Healthcare Royalty) is a private equity subsidiary of Cowen, Inc. founded in 2007 by Gregory Brown. The firm is headquartered in Stamford, Connecticut. | Investment Managers | Corporate Officer/Principal | |
Oxagen Ltd.
![]() Oxagen Ltd. Pharmaceuticals: MajorHealth Technology Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member |
Statistiques
Internationale
Etats-Unis | 20 |
Allemagne | 14 |
Royaume-Uni | 10 |
Suisse | 5 |
Belgique | 3 |
Sectorielle
Health Technology | 33 |
Consumer Services | 10 |
Finance | 5 |
Commercial Services | 4 |
Producer Manufacturing | 2 |
Opérationnelle
Director/Board Member | 29 |
Corporate Officer/Principal | 21 |
Chief Tech/Sci/R&D Officer | 10 |
Founder | 9 |
Doctorate Degree | 7 |
Relations les plus connectées
Insiders | |
---|---|
Michael Carter | 22 |
Patrick Baeuerle | 19 |
Christian Itin | 12 |
Malte Peters | 11 |
Jens Hennecke | 6 |
Torsten Dreier | 5 |
- Bourse
- Insiders
- Erich Felber
- Connexions Sociétés